Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacterium lactis CECT8145

Also known as: Bifidobacterium lactis CECT8145, B. lactis CECT8145, Bifidobacterium animalis subsp. lactis, Bifidobacterium animalis subsp. lactis CECT 8145

Overview

Bifidobacterium animalis subsp. lactis CECT 8145 is a specific strain of beneficial bacteria classified as a probiotic. This strain naturally resides in the human gastrointestinal tract and is increasingly utilized in fermented foods and dietary supplements to support gut health. Research on B. lactis CECT8145 is emerging, focusing on its potential to manage obesity-related disorders, alleviate gastrointestinal symptoms, and improve metabolic health. While the evidence base is growing, including systematic reviews and randomized controlled trials, it is still considered limited compared to more established probiotic strains. Its application is rooted in its ability to modulate the gut microbiota and influence host physiological processes, offering a promising avenue for improving overall well-being.

Benefits

Bifidobacterium lactis CECT8145 shows promising, evidence-based benefits across several health domains. For gastrointestinal health, systematic reviews of B. animalis subsp. lactis (including strains like CECT8145) indicate significant improvements in symptoms such as abdominal pain and overall gut health, suggesting its utility in managing digestive discomfort. Specifically for obesity and metabolic health, experimental studies have identified CECT8145 as a potential aid in reducing body fat and improving metabolic markers. This is further supported by broader systematic reviews on the Bifidobacterium genus, which highlight its role in managing overweight and obesity. Furthermore, an RCT in dogs demonstrated that CECT8145 improved glycemic and insulinemic responses, modulated gut microbiota, and reduced systemic inflammation, suggesting potential benefits for glucose metabolism and inflammation control in humans, pending further research. While not specific to CECT8145, other B. animalis strains have shown efficacy in treating pediatric atopic dermatitis, hinting at broader immunomodulatory effects.

How it works

Bifidobacterium lactis CECT8145 primarily exerts its beneficial effects by modulating the gut microbiota, promoting the growth of beneficial bacteria while potentially suppressing pathogenic species. This leads to an improved balance within the gut ecosystem. The strain is also believed to enhance gut barrier function, which can reduce the translocation of harmful substances and subsequently decrease systemic inflammation by influencing immune signaling pathways. Furthermore, CECT8145 appears to impact host metabolism by improving insulin sensitivity and regulating glucose levels. This metabolic effect may be mediated through the production of short-chain fatty acids, which interact with host metabolic receptors. Both live and heat-treated forms of the strain have demonstrated biological activity, indicating diverse mechanisms of action, though live bacteria are generally considered more effective for colonization.

Side effects

Bifidobacterium animalis subsp. lactis strains, including CECT8145, are generally considered safe for consumption. No significant adverse effects have been widely reported in human or animal studies. When side effects do occur, they are typically mild and transient, primarily involving gastrointestinal discomfort such as bloating or gas, especially during the initial days of supplementation as the gut microbiota adjusts. These effects are rare and usually resolve on their own. There are no documented significant drug interactions or contraindications specifically associated with B. lactis CECT8145. While generally safe, caution is advised for individuals with severely compromised immune systems, though no specific concerns have been raised for this particular strain in such populations. Overall, its safety profile is robust, making it a well-tolerated supplement for most individuals.

Dosage

Specific dosing guidelines for Bifidobacterium lactis CECT8145 are not yet standardized across all applications. However, research studies typically employ daily dosages ranging from 10^9 to 10^11 colony-forming units (CFU). The optimal dosage can vary depending on the intended health benefit and the specific formulation of the supplement. It is often suggested that taking probiotics with meals may enhance their survival through the acidic environment of the stomach, thereby improving their efficacy. Both live and heat-treated forms of B. lactis CECT8145 have been investigated for their biological activities, but live probiotic bacteria are generally preferred for their ability to colonize the gut and exert their full range of beneficial effects. There are no established upper limits or safety thresholds that have been exceeded in studies, reinforcing its generally safe profile.

FAQs

Is B. lactis CECT8145 effective for weight loss?

Evidence suggests it may help reduce body fat and improve metabolic markers, but it should be used as part of a comprehensive healthy lifestyle, not as a standalone weight loss solution.

Can it help with digestive issues?

Yes, studies indicate it may alleviate gastrointestinal symptoms like abdominal pain and contribute to overall improved gut health by modulating the gut microbiota.

Is it safe for children?

While Bifidobacterium strains are generally considered safe for children, specific studies on B. lactis CECT8145 in pediatric populations are limited, so consult a healthcare professional.

How soon do benefits appear?

Effects on gut symptoms may be noticeable within a few weeks of consistent use. Metabolic benefits, such as improvements in body composition, may require longer-term supplementation.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/34918142/ – This systematic review and meta-analysis found that B. animalis subsp. lactis supplementation significantly reduced gastrointestinal symptoms in adults. The study included multiple RCTs, confirming the efficacy of this probiotic for gut health, though it noted heterogeneity in strains and dosing.
https://pubmed.ncbi.nlm.nih.gov/32524647/ – This network meta-analysis on probiotics for pediatric atopic dermatitis identified B. animalis strains as effective, suggesting their immunomodulatory potential. While not specific to CECT8145, it supports the broader benefits of the species.
https://pubs.acs.org/doi/abs/10.1021/acs.jafc.5b05934?journalCode=jafcau – This experimental study identified B. lactis CECT8145 as a promising probiotic for obesity disorders, demonstrating reductions in body fat and improvements in metabolic markers in animal models. It provides mechanistic insights but highlights the need for human trials.
https://www.tandfonline.com/doi/full/10.1080/27697061.2024.2320192 – This recent systematic review supports the role of Bifidobacterium genus probiotics in reducing body fat mass and managing overweight and obesity. It aligns with findings on CECT8145 and emphasizes the importance of strain-specific randomized controlled trials.
https://pubmed.ncbi.nlm.nih.gov/39320367/ – This randomized controlled trial in adult dogs showed that both live and heat-treated B. lactis CECT8145 improved glycemic and insulinemic responses, modulated fecal microbiota, and reduced systemic inflammation biomarkers. This demonstrates safety and metabolic benefits with potential for human translation.